Lower numbers = closer to natural. Higher numbers = more enhanced.
Why this rating?
Pramlintide is a synthetic analog of amylin, a satiety hormone co-secreted with insulin from pancreatic beta cells after meals. It regulates blood glucose by slowing gastric emptying, promoting satiety via hypothalamic receptors, and suppressing inappropriate glucagon secretion. It is not anabolic and does not affect testosterone, muscle building or athletic performance. FDA-approved in 2005 as an adjunct to mealtime insulin, it produces modest weight loss as a secondary effect. Rated 3, consistent with the incretin/amylin satiety-agent class.
Overview
An injectable synthetic analog of the beta-cell hormone amylin, sold as Symlin. It is FDA-approved as an adjunct to mealtime insulin in type 1 and type 2 diabetics who have not reached glucose targets on insulin alone. It slows gastric emptying, promotes satiety and blunts post-meal glucagon, smoothing post-meal glucose spikes and producing modest weight loss. Notably, pramlintide is the amylin analog that is actually FDA-approved for human use, unlike cagrilintide, the newer long-acting amylin analog still in development for obesity.
Important Warnings
- •BOXED WARNING: severe insulin-induced hypoglycemia, particularly in type 1 diabetes, reduce mealtime insulin by 50% at initiation
- •Only used together with mealtime insulin; not a standalone weight-loss drug
- •Do not mix with insulin in the same syringe. Inject separately
- •Avoid in hypoglycemia unawareness or poor self-monitoring
Purpose & Use Cases
Post-Meal Glucose Control
Adjunct to mealtime insulin: blunts post-meal glucose spikes by slowing gastric emptying and suppressing glucagon. FDA-approved for type 1 and type 2 diabetics on insulin.
Satiety / Appetite Reduction
Amylin-receptor agonism promotes satiety, which reduces food intake and contributes modest weight loss in insulin-treated type 2 diabetics.
Amylin Replacement
People with diabetes are deficient in amylin as well as insulin; pramlintide restores part of that missing amylin signal.
Benefits
- FDA-approved amylin analog with an established safety label
- Smooths post-meal glucose spikes as an insulin adjunct
- Promotes satiety and modest weight loss
- Suppresses inappropriate post-meal glucagon
- Works through a pathway separate from (and complementary to) insulin
Good to Know
The FDA-approved amylin: cagrilintide is the newer one
Pramlintide is the amylin analog that is actually approved for human use (Symlin, 2005). It is short-acting and dosed before meals. Cagrilintide is the newer, long-acting once-weekly amylin analog being developed for obesity (best known as the amylin half of CagriSema). Same hormone family, but pramlintide is the established, approved member.
Why not just use native amylin
Human amylin is highly amyloidogenic. It aggregates into amyloid fibrils and is effectively unusable as a drug. Pramlintide swaps in proline residues from rat amylin to block that aggregation while keeping the satiety and glucose-regulating activity.
The real danger is hypoglycemia, not the amylin itself
Pramlintide alone does not cause hypoglycemia, but it is always used with insulin, and that combination can cause severe lows (the boxed warning). That is why mealtime insulin is cut by half when starting and glucose is monitored closely.
Not anabolic and not WADA-banned
Pramlintide works through satiety and glucose control, not any performance or anabolic pathway, and amylin-class agents are not on the WADA Prohibited List. Any weight loss is modest and appetite-driven. It does nothing to build or hold muscle.
Dosage Guidelines
| Experience Level | Dosage Range |
|---|---|
| Beginner | 45 – 90 mcg/day |
| Intermediate | 90 – 180 mcg/day |
| Advanced | 180 – 360 mcg/day |
FDA label doses are per-injection, given before each of roughly 3 major meals/day. The ranges above are the equivalent daily totals. Type 1 diabetes: start at 15 mcg/meal, titrate in 15 mcg steps (once no clinically significant nausea for 3+ days) to a 30-60 mcg/meal maintenance dose (~90-180 mcg/day). Type 2 diabetes: start at 60 mcg/meal, titrate to a 120 mcg/meal maintenance dose (~180-360 mcg/day). Mealtime insulin must be reduced by 50% when starting, to limit hypoglycemia. Long-term adjunct therapy, not a short cycle.
Side Effects
Severe Insulin-Induced Hypoglycemia
commonThe subject of the boxed warning. Pramlintide added to insulin increases the risk of severe hypoglycemia, particularly in type 1 diabetes, usually within the first 3 hours of a dose. In placebo-controlled trials, patient-ascertained severe hypoglycemia occurred in ~16.8% of type 1 patients on Symlin vs 10.8% on placebo (medically-assisted: 7.3% vs 3.3%).
Reduce mealtime insulin by 50% when starting; monitor glucose frequently; do not use in people with hypoglycemia unawareness or poor compliance.
Nausea
very commonThe most common non-hypoglycemic side effect, from delayed gastric emptying; usually worst early and eases with time.
Titrate slowly; smaller meals.
Vomiting / Anorexia
commonGI effects and reduced appetite are common, consistent with the satiety mechanism.
Slow titration; stay hydrated.
Injection Site Reactions
uncommonMild redness or irritation at the injection site.
Rotate injection sites.
Headache
commonReported more frequently than placebo in trials, particularly in type 2 diabetes (13% vs 7% with placebo).
Usually mild and self-limited; ensure adequate hydration.
General Mitigation Strategies
The dominant safety issue is hypoglycemia when combined with insulin (boxed warning). Mealtime insulin must be cut by 50% at initiation and glucose monitored closely, especially in type 1 diabetes. GI/nausea side effects are dose-dependent and improve with slow titration. Pramlintide and insulin must be injected separately (do not mix in the same syringe) and at separate sites.
Post Cycle Therapy (PCT)
Not hormonal (in the anabolic sense). Does not affect the HPTA. No PCT required.
How It Works
Pramlintide is a synthetic analog of human amylin in which proline substitutions (borrowed from the less amyloidogenic rat amylin) prevent the aggregation that makes native human amylin unusable as a drug. It complements insulin by acting on a separate pathway: it slows gastric emptying, promotes satiety through hypothalamic amylin receptors, and suppresses inappropriate glucagon secretion after meals. The result is reduced post-meal glucose excursions. Its plasma half-life is short (~48 minutes), so it is injected before each major meal rather than once weekly.
Fundamentals
Reference on the practices relevant to Pramlintide: how they are done and where they go wrong. Not a recommendation to use it.
Legal Status
FDA-approved (Symlin, March 2005) in the USA. Carries a boxed warning for severe insulin-induced hypoglycemia.
Legal status varies by country and changes over time. This is a general summary, not legal advice.
WADA Status
Pramlintide (Symlin) is not listed on the WADA Prohibited List. Amylin/incretin-class metabolic agents are not currently prohibited; athletes in tested sport should verify the current list before competition.